Global GLP-1 Analogues Market Size study, by Product (Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Trulicity, Mounjaro, Zepbound, Soliqua, Xultophy, Bydureon, Other products), by Format (Single-dose, Multi-dose, Tablets), by Route of Administration (Subcu

Global GLP-1 Analogues Market Size study, by Product (Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Trulicity, Mounjaro, Zepbound, Soliqua, Xultophy, Bydureon, Other products), by Format (Single-dose, Multi-dose, Tablets), by Route of Administration (Subcutaneous, Oral), by Indication (Diabetes, Obesity, Other indications), by End User (Hospitals and Specialty Clinics, Long-term Care Facilities, Home Care Settings) and Regional Forecasts 2022-2032

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. GLP-1 analogue drugs have witnessed significant acceptance, particularly after their benefits in chronic obesity and weight management became widely known. This class of drugs, referred to as incretin mimetics, aids in regulating blood glucose levels and promoting satiety, making them crucial in treating diabetes and obesity. The market is driven by a strong R&D pipeline, with many key players developing innovative products and novel indications.

The GLP-1 analogues market is experiencing robust growth due to a strong research and development (R&D) pipeline aimed at advancing treatments for type 2 diabetes and obesity. Pharmaceutical companies are heavily investing in developing new and improved GLP-1 receptor agonists to enhance efficacy, safety, and patient convenience. For example, Novo Nordisk is exploring once-weekly oral formulations of semaglutide, which have shown promising results in reducing HbA1c levels and promoting weight loss. Additionally, Eli Lilly's tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated superior efficacy in clinical trials compared to existing GLP-1 therapies. These advancements are fueling the market's expansion, as companies strive to address the growing global burden of diabetes and obesity. Moreover, the extended therapeutic uses and development of oral GLP-1 Analogues present various lucrative opportunities over the forecast years. However, the high entry barriers due to duopoly and non-adherence to therapy are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for Global GLP-1 Analogues Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global GLP-1 Analogues Market in terms of revenue. The market growth in the region is being attributed to factors including the high prevalence of type 2 diabetes and obesity, advanced healthcare infrastructure, and the strong presence of key pharmaceutical companies such as Novo Nordisk, Eli Lilly, and Pfizer. Whereas, the market in the Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by the increasing prevalence of diabetes and obesity, rising healthcare awareness, and improving access to advanced medical treatments. Countries such as China and India are witnessing a surge in diabetes cases due to urbanization, sedentary lifestyles, and changing dietary habits, driving the demand for effective diabetes management solutions.

Major market player included in this report are:

Novo Nordisk A/S

Eli Lilly and Company

Sanofi

AstraZeneca

Boehringer Ingelheim International GmbH

Innovent

Hanmi Pharm

Zealand Pharma A/S

Pfizer, Inc.

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Company

Roche Holding AG

The detailed segments and sub-segment of the market are explained below:

By Product:

Ozempic

Wegovy

Rybelsus

Saxenda

Victoza

Trulicity

Mounjaro

Zepbound

Soliqua

Xultophy

Bydureon

Other products

By Format:

Single-dose

Multi-dose

Tablets

By Route of Administration:

Subcutaneous

Oral

By Indication:

Diabetes

Obesity

Other indications

By End User:

Hospitals and Specialty Clinics

Long-term Care Facilities

Home Care Settings

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.